Background:

D-3263 is an agonist of transient receptor potential melastatin member 8 (TRPM8) with potential antineoplastic activity.

D-3263 induces calcium flux and cell death in in vitro cells expressing TRPM8[1].

D-3263 (50 or 100 mg/kg/d) alone or with Finasteride (10 mg/kg/d) results in reduction in prostate hyperplasia of rats with evidence of a dose response. The highest dose of the TRPM8 agonist D-3263, given in combination with Finasteride, results in lower prostate weights than the highest dose of D-3263 or Finasteride given alone, suggesting a potential additive effect[1].

[1]. David Duncan, et al. PRECLINICAL EVALUATION OF THE TRPM8 ION CHANNEL AGONIST D-3263 FOR BENIGN PROSTATIC HYPERPLASIA. THE JOURNAL OF UROLOGY, Vol. 181, No. 4, Supplement, Tuesday, April 28, 2009